These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 28918657)

  • 1. Direct Oral Anticoagulant Use in Atypical Thrombosis-Related Conditions.
    Chang C; Hoyos M; Owusu Y; Elewa H
    Ann Pharmacother; 2018 Feb; 52(2):185-197. PubMed ID: 28918657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants. Results from an international patient-level data meta-analysis.
    Dufrost V; Risse J; Reshetnyak T; Satybaldyeva M; Du Y; Yan XX; Salta S; Gerotziafas G; Jing ZC; Elalamy I; Wahl D; Zuily S
    Autoimmun Rev; 2018 Oct; 17(10):1011-1021. PubMed ID: 30103045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recurrent Thrombosis With Direct Oral Anticoagulants in Antiphospholipid Syndrome: A Systematic Literature Review and Meta-analysis.
    Sanchez-Redondo J; Espinosa G; Varillas Delgado D; Cervera R
    Clin Ther; 2019 Sep; 41(9):1839-1862. PubMed ID: 31405527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct oral anticoagulants versus warfarin in patients with antiphospholipid syndrome: A meta-analysis of randomized controlled trials.
    Lee YH; Song GG
    Lupus; 2022 Oct; 31(11):1335-1343. PubMed ID: 35968627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct Oral Anticoagulants Use in Antiphospholipid Syndrome: Are These Drugs an Effective and Safe Alternative to Warfarin? A Systematic Review of the Literature.
    Dufrost V; Risse J; Zuily S; Wahl D
    Curr Rheumatol Rep; 2016 Dec; 18(12):74. PubMed ID: 27812956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct oral anticoagulants in antiphospholipid syndrome: Meta-analysis of randomized controlled trials.
    Dufrost V; Wahl D; Zuily S
    Autoimmun Rev; 2021 Jan; 20(1):102711. PubMed ID: 33197580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolving Treatments for Arterial and Venous Thrombosis: Role of the Direct Oral Anticoagulants.
    Chan NC; Eikelboom JW; Weitz JI
    Circ Res; 2016 Apr; 118(9):1409-24. PubMed ID: 27126650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Case-fatality of recurrent venous thromboembolism and major bleeding associated with aspirin, warfarin, and direct oral anticoagulants for secondary prevention.
    Wu C; Alotaibi GS; Alsaleh K; Linkins LA; McMurtry MS
    Thromb Res; 2015 Feb; 135(2):243-8. PubMed ID: 25488466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombosis of atypical location: how to treat patients in the era of direct oral anticoagulants?
    Mimier MK; Janczak DT; McBane RD; Houghton DE; Wysokinski WE
    Pol Arch Intern Med; 2018 Oct; 128(10):604-608. PubMed ID: 30233080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct oral anticoagulants versus warfarin in patients with single or double antibody-positive antiphospholipid syndrome.
    Williams B; Saseen JJ; Trujillo T; Palkimas S
    J Thromb Thrombolysis; 2022 Jul; 54(1):67-73. PubMed ID: 34817786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct oral anticoagulants versus warfarin in patients with single antibody-positive anti-phospholipid syndrome.
    Liu A; Rupani KV; Naymagon L
    Eur J Haematol; 2022 Jul; 109(1):69-74. PubMed ID: 35305281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Choice of anticoagulation in patients with low risk antiphospholipid syndrome.
    Bakow BR; Phung Q; Rabinovich D; Olszewski AJ; Reagan JL
    J Thromb Thrombolysis; 2023 Jul; 56(1):121-127. PubMed ID: 37219825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticoagulation prescribing patterns in patients with cancer.
    Xiang E; Ahuja T; Raco V; Cirrone F; Green D; Papadopoulos J
    J Thromb Thrombolysis; 2018 Jan; 45(1):89-98. PubMed ID: 29052104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using direct oral anticoagulants (DOACs) in cancer and other high-risk populations.
    van Es N; Büller HR
    Hematology Am Soc Hematol Educ Program; 2015; 2015():125-31. PubMed ID: 26637711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging therapeutic uses of direct-acting oral anticoagulants: An evidence-based perspective.
    Raschi E; Bianchin M; De Ponti R; De Ponti F; Ageno W
    Pharmacol Res; 2017 Jun; 120():206-218. PubMed ID: 28366835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct oral anticoagulants in antiphospholipid syndrome: a real life case series.
    Betancur JF; Bonilla-Abadía F; Hormaza AA; Jaramillo FJ; Cañas CA; Tobón GJ
    Lupus; 2016 May; 25(6):658-62. PubMed ID: 26743321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of anticoagulant agents in patients with venous thromboembolism and cancer: A network meta-analysis.
    Vedovati MC; Giustozzi M; Bonitta G; Agnelli G; Becattini C
    Thromb Res; 2018 Oct; 170():175-180. PubMed ID: 30196195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk and benefit of direct oral anticoagulants or PAR-1 antagonists in addition to antiplatelet therapy in patients with acute coronary syndrome.
    Gao F; Shen H; Wang ZJ; Yang SW; Liu XL; Zhou YJ
    Thromb Res; 2015 Aug; 136(2):243-9. PubMed ID: 26037286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of direct oral anticoagulants in patients on immunomodulatory agents.
    Man L; Morris A; Brown J; Palkimas S; Davidson K
    J Thromb Thrombolysis; 2017 Oct; 44(3):298-302. PubMed ID: 28819709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct oral anticoagulant use in patients with thrombophilia, antiphospholipid syndrome or venous thrombosis of unusual sites: A narrative review.
    Bertoletti L; Benhamou Y; Béjot Y; Marechaux S; Cheggour S; Aleil B; Lellouche N; Dillinger JG; Delluc A
    Blood Rev; 2018 Jul; 32(4):272-279. PubMed ID: 29402471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.